Contact and Acknowledgements
LYMPHOMA CONNECT
Bodenackerstrasse 17
4103 Bottmingen
Switzerland
Or for more information visit cor2ed.com
Dr. Froukje Sosef MD
Phone: +31 6 2324 3636
froukje.sosef@cor2ed.com
Select Page
Dr. Daniel Persky, MD
Dr. Persky serves as an Associate Professor of Medicine at the University of Arizona College of Medicine. He is currently the Associate Director of Clinical Investigations and Director, Clinical Trial Office. He specializes in Hematology/Oncology, particularly in lymphoid malignancies, such as lymphoma, CLL, and others.
Dr. Persky received his Bachelor’s Degree from Harvard University and his medical degree from the Albert Einstein College of Medicine in New York. He completed his internship and residency at the Mayo Graduate School of Medicine in Rochester, Minnesota, then returned to New York to complete a three-year fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center.
Relevant Publications
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, and Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26(14):2258-2263.
https://www.ncbi.nlm.nih.gov/pubmed/18413640
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high risk limited stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015;125(2):236-241.
https://www.ncbi.nlm.nih.gov/pubmed/25395425
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma. 2016;57(10):2359-2369.
https://www.ncbi.nlm.nih.gov/pubmed/26758422
Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, Von Gehr A, LeBlanc M, Fisher RI, Smith SM, Friedberg JW. A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. Am J Hematol. 2018;93(4):486-493.
https://www.ncbi.nlm.nih.gov/pubmed/29266344
Kelly KR, Friedberg JW, Park SI, McDonagh KT, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen PJ, Padmanabhan Iyer S, Stefanovic A, Bernstein SH, Weitman S, Karnad AB, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/vincristine in Relapsed/refractory Aggressive B-cell Lymphoma. Clin Cancer Res. 2018 [Epub ahead of print].
https://www.ncbi.nlm.nih.gov/pubmed/30082475
Persky DO. Limited-stage DLBCL: it’s patient selection. Blood. 2018;131(2): 155-156.
https://www.ncbi.nlm.nih.gov/pubmed/29326347
Dr. Mats Jerkeman, MD
Dr. Mats Jerkeman, MD, completed his training in Clinical Oncology at Lund University, Sweden, where he is currently Adjunct Professor in Clinical Oncology. His research focuses on the development of clinical trials in lymphoma, and in clinical epidemiology. He is Chairman of the Swedish Lymphoma Group, Vice Chairman of the Nordic Lymphoma Group, and Editor of the ESMO Guidelines of Lymphoma.
Relevant Publications
Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D’Amore F, Nilsson-Ehle H, Jensen P, Pedersen M, Geisler CH, Jerkeman M. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood. 2014;124(8):1288-95.
https://www.ncbi.nlm.nih.gov/pubmed/24859361
Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, Gronbaek K, Sundberg J, Pedersen LB, Ralfkiaer E, Karjalainen-Lindsberg ML, Sundstrom C, Ehinger M, Geisler C, Jerkeman M. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood. 2016;128(14):1814-20.
https://www.ncbi.nlm.nih.gov/pubmed/27354719
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770-8.
https://www.ncbi.nlm.nih.gov/pubmed/26673811
Ek S, Dictor M, Jerkeman M, Jirstrom K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. 2008;111(2):800-5.
https://www.ncbi.nlm.nih.gov/pubmed/17934069
El-Galaly TC, Jakobsen LH, Hutchings M, de Nully Brown P, Nilsson-Ehle H, Szekely E, Mylam KJ, Hjalmar V, Johnsen HE, Bogsted M, Jerkeman M. Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. J Clin Oncol. 2015;33(34):3993-8.
https://www.ncbi.nlm.nih.gov/pubmed/26438115
Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570-7.
https://www.ncbi.nlm.nih.gov/pubmed/25006130
Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann C, Raty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Gronbaek K. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903-10.
https://www.ncbi.nlm.nih.gov/pubmed/28819011
Jerkeman M, Anderson H, Cavallin-Stahl E, Dictor M, Hagberg H, Johnson A, Kaasa S, Kvaloy S, Sundstrom C, Akerman M. CHOP versus MACOP-B in aggressive lymphoma–a Nordic Lymphoma Group randomised trial. Ann Oncol. 1999;10(9):1079-86.
https://www.ncbi.nlm.nih.gov/pubmed/10572606
Jerkeman M, Eskelund CW, Hutchings M, Raty R, Fahl Wader K, Laurell A, Toldbod H, Pedersen LB, Niemann C, Dahl C, Kuitunen H, Geisler C, Gronbaek K, Kolstad A. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109-e116.
https://www.ncbi.nlm.nih.gov/pubmed/29396091
Wästerlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D’Amore F, Jerkeman M. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013;24(7):1879-86.
https://www.ncbi.nlm.nih.gov/pubmed/23446093
Dr. Paul M. Barr, MD
Paul M. Barr MD is an Associate Professor of Medicine at the University of Rochester Medical Center in Rochester, New York. He received his MD from Northeastern Ohio Medical University. His internal medicine and hematology / oncology training was completed at Case Western Reserve University where he also served as Chief Medical Resident. Joining the University of Rochester lymphoma program in 2010, his primary research focus is on novel drug development for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Current efforts revolve around the development of novel combinations incorporating inhibitors targeting the B cell receptor signaling pathway, supported by the Lymphoma Research Foundation and Hope Foundation. Beyond his individual research interests, he is a strong advocate for oncology clinical research. He serves as the Medical Director of the Clinical Trials Office for the Wilmot Cancer Center overseeing all industry sponsored, cooperative group and investigator initiated studies.
Relevant Publications
Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW. RCHOP, radioimmunotherapy and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2 multicenter study. Lancet Haematology. 2018. Mar;5(3):e102-e108. https://www.ncbi.nlm.nih.gov/pubmed/29396094
Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, ZhouL, Scherle P, X Chen, and Barr PM. Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood 2018. Jul 19;132(3):293-306. https://www.ncbi.nlm.nih.gov/pubmed/29695516
Persky DO; Li H; Rimsza LM; Barr PM; Popplewell LL; Bane CL; Von Gehr A; LeBlanc M; Fisher RI; Smith SM; Friedberg JW A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806.American journal of hematology.2017;Aug;93(4):486-493. https://www.ncbi.nlm.nih.gov/pubmed/29266344
Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA, Friedberg JW. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017 Jun 1;129(22):3037-3039. https://www.ncbi.nlm.nih.gov/pubmed/28325864
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017 Mar;176(5):759-769. https://www.ncbi.nlm.nih.gov/pubmed/27992063
Hunter BD, Herr M, Meacham PJ, Barlaskar F, Evans AG, Burack WR, Liesveld JL, Becker MW, Milner LA, Constine LS, Dhakal S, Barr PM, Friedberg JW, Casulo C. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):145-151. https://www.ncbi.nlm.nih.gov/pubmed/27998707
Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors JM; Gascoyne RD; Hiddemann W; Unterhalt M; Weinstock DM; Weigert O. Prospective Clinicogenetic Risk Models To Predict Early Progression of Follicular Lymphoma after First-Line Immunochemotherapy Blood. 2016 2016 Aug 25;128(8):1112-20. https://www.ncbi.nlm.nih.gov/pubmed/27418643
Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM. Recommendations for Clinical Trial Development in Follicular Lymphoma. J Natl Cancer Inst. 2016 Dec 31;109(3). https://www.ncbi.nlm.nih.gov/pubmed/28040699
Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O’Brien SM; Liem AK; McIntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J; Hu J; Dreiling LK; Friedberg JW “Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.” Blood. 2016; May 19;127(20):2411-5. https://www.ncbi.nlm.nih.gov/pubmed/26968534
Reagan PM, Baran A, Kelly JL, Barr PM, Casulo C, Chengazi VU, Friedberg JW. Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):322-328. https://www.ncbi.nlm.nih.gov/pubmed/27130328
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. Journal of Clinical Oncology. 2015 Jul 20;33(21):2399-404. https://www.ncbi.nlm.nih.gov/pubmed/26077240
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CS, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, and Briehl MM. Phase II study of imexon, a pro-oxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2014 Aug 21;124:1259-65. https://www.ncbi.nlm.nih.gov/pubmed/25016003
Hutchinson K, Jahangiri S, Calvi LM, Barr PM, Friedberg JW, Kelly JL. Impact of dietary supplements, obesity, and treatment initiation on serum vitamin D levels in lymphoma patients. Leukemia & lymphoma. 2014 Jul 15:1-4. https://www.ncbi.nlm.nih.gov/pubmed/24794808
Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW. Phase I Trial of Fludarabine, Bortezomib and Rituximab for Relapsed and Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma. British Journal of Hematology 2009; 147(1):89-96. https://www.ncbi.nlm.nih.gov/pubmed/19656151
Dr. Jessica Okosun, MD, PhD
Dr. Jessica Okosun is a Cancer Research UK Clinician Scientist at the Barts Cancer Institute and an Honorary Consultant Haematologist at St Bartholomew’s Hospital, London UK, specialising in lymphomas. She received her BA in Natural Sciences (Pathology) and qualified in medicine from the University of Cambridge in 2004. She was a recipient of the Kay Kendall Leukaemia Fund’s Junior Research Fellowship, completing her PhD in 2015 from Queen Mary, University of London. Her research interests are focussed on understanding the origin, heterogeneity and evolution of lymphomas, particularly follicular lymphomas, in a bid to define novel biomarkers and therapeutic strategies. Her research has led to several awards including the EHA/ASH Translational Research Training in Haematology award and the UK’s Royal College of Pathologist Specialty Research Medal in Haematology.
She is an active member of the UK’s National Cancer Research Institute (NCRI) High Grade Lymphoma Subgroup, Hodgkin lymphoma subgroup and the Primary CNS Lymphoma (PCNSL) Working Party. She chairs the Barts Cancer Centre’s Patient and Public Research Advisory Group.
Relevant Publications
Heward JA, Kumar EA, Korfi K, Okosun J, Fitzgibbon J. Precision medicine and lymphoma. Current Opinion in Hematology. 2018 Jul;25(4):329-334.
https://www.ncbi.nlm.nih.gov/pubmed/29738334
Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J, Clear A, Iqbal S, Davies J, Johnson P, Calaminici M, Montoto S, Auer R, Chelala C, Gribben J, Graham T, Fest T, Fitzgibbon J, Okosun J. Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma. Leukemia. 2018; 32(5):1258-1263
https://www.ncbi.nlm.nih.gov/pubmed/29568095
Araf S, Okosun J, Fitzgibbon J. Predicting early relapse in follicular lymphoma: have we turned a corner? Lancet Oncology. 2018;19(4):441-442
https://www.ncbi.nlm.nih.gov/pubmed/29475722
Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A, Chan W, Sasca D, Yiangou L, Osaki H, Basheer F, Gallipoli P, Burrows N, Erdem A, Sybirna A, Foerster S, Zhao W, Sustic T, Harrison AP, Laurenti E, Okosun J, Hodson D, Wright P, Smith KG, Maxwell P, Fitzgibbon J, Du MQ, Adams DJ, Huntly BJP. Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nature Cell Biology. 2017 Sep;19(9):1093-1104
https://www.ncbi.nlm.nih.gov/pubmed/28825697
Mansouri L, Noerenberg D, Young E, Mylonas E, Abdulla M, Frick M, Asmar F, Ljungström V, Schneider M, Yoshida K, Skaftason A, Pandzic T, Gonzalez B, Tasidou A, Waldhueter N, Rivas-Delgado A, Angelopoulou M, Ziepert M, Arends CM, Couronné L, Lenze D, Baldus CD, Bastard C, Okosun J, Fitzgibbon J, Dörken B, Drexler HG, Roos-Weil D, Schmitt CA, Munch-Petersen HD, Zenz T, Hansmann ML, Strefford JC, Enblad G, Bernard OA, Ralfkiaer E, Erlanson M, Korkolopoulou P, Hultdin M, Papadaki T, Grønbæk K, Lopez-Guillermo A, Ogawa S, Küppers R, Stamatopoulos K, Stavroyianni N, Kanellis G, Rosenwald A, Campo E, Amini RM, Ott G, Vassilakopoulos TP, Hummel M, Rosenquist R, Damm F. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood. 2016 Dec 8;128(23):2666-2670
https://www.ncbi.nlm.nih.gov/pubmed/27670424
Okosun J, Montoto S, Fitzgibbon J. The routes for transformation of follicular lymphoma. Current Opinion in Hematology. 2016 Jul;23(4):385-91
https://www.ncbi.nlm.nih.gov/pubmed/2713597
Kotsiou E, Okosun J, Besley C, Iqbal S, Matthews J, Fitzgibbon J, Gribben JG, Davies JK. TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. Blood. 2016 Jul 7;128(1):72-81.
https://www.ncbi.nlm.nih.gov/pubmed/27103745
Okosun J*, Wolfson RL*, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics. 2016 Feb;48(2):183-8 *joint co-author
https://www.ncbi.nlm.nih.gov/pubmed/26691987
Okosun J, Packham G, Fitzgibbon J. Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies. Expert Opinion on Investigational Drugs. 2014; 23(10):1321-32
https://www.ncbi.nlm.nih.gov/pubmed/24855903
Okosun J*, Bödör C*, Wang J*, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, Tawana K, Popov N, O’Riain C, O’Shea D, Carlotti E, Davies A, Lawrie CH, Matolcsy A, Calaminici M, Norton A, Byers RJ, Mein C, Stupka E, Lister TA, Lenz G, Montoto S, Gribben JG, Fan Y, Grosschedl R, Chelala C, Fitzgibbon J. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics. 2014; 46(2):176-81 *joint first authors
https://www.ncbi.nlm.nih.gov/pubmed/24362818
Bödör C, Grossmann V, Popov N, Okosun J, O’Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA, Elemento O, Hills R, Gribben JG, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013; 122(18):3165-8
https://www.ncbi.nlm.nih.gov/pubmed/24052547
Montoto S, Shaw K, Okosun J, Gandhi S, Fields PA, Wilson AM, Shanyinde M, Cwynarski K, Marcus R, de Vos J, Young AM,Tenant-Flowers M, Orkin C, Johnson M, Chilton D, Gribben JG, Bower M. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. Journal of Clinical Oncology. 2012; 30(33):4111-6
https://www.ncbi.nlm.nih.gov/pubmed/23045581
Dr. Massimo Magagnoli, MD
Dr. Massimo Magagnoli is a haematologist and Associate Director at the Department of Hematology and Clinical Oncology at the Humanitas Cancer Center in Milan. He graduated in medicine from the University of Bologna, where he attended the “Seragnoli” hematology institute, first as a medical student and later as a doctor in specialization. At this institute he specialized in hematology with laude. Since 1999 he works at Humanitas Cancer Center. Dott Magagnoli specializes in the management of non-Hodgkin’s lymphomas and chronic lymphatic leukemia. Particular interest is in the study and research of new drugs for lymphoma and chronic lymphatic leukemia. From 1999, he followed and participated in more than 40 Phase I, II and III clinical trials in hematologic malignancies. Last GCP training (ICH E6 (R2) GCP) on November 2017. Dr. Magagnoli other interests in the management of older patients with haematological tumors, and tools to improve the care of this patient population.
Massimo is co-author of about 80 peer-reviewed papers
Relevant Publications
Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, Orcioni GF, Ascani S, Simoni R, Pileri SA, Tura S. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.J Clin Oncol. 2000 Jul;18(13):2603-6. https://www.ncbi.nlm.nih.gov/pubmed/10893292
Zinzani PL, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, Guardigni L, Mazza P, Marra R, Ronconi F, Lauta VM, Bendandi M, Gherlinzoni F, Gentilini P, Ciccone F, Cellini C, Stefoni V, Ricciuti F, Gobbi M, Tura S. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol. 2000 Feb;18(4):773-9.
https://www.ncbi.nlm.nih.gov/pubmed/10673518
Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L, Resegotti L. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood. 2000 Feb 1;95(3):783-9.
https://www.ncbi.nlm.nih.gov/pubmed/10648386
Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F, Molica S, Zaccaria A, Cantonetti AM, Gentilini P, Guardigni L, Gherlinzoni F, Ribersani M, Bendandi M, Albertini P, Tura S Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol. 1999 Apr;17(4):1254.
https://www.ncbi.nlm.nih.gov/pubmed/10561186
Zinzani PL, Martelli M, Magagnoli M, Pescarmona E, Scaramucci L, Palombi F, Bendandi M, Martelli MP, Ascani S, Orcioni GF, Pileri SA, Mandelli F, Tura S. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood. 1999 Nov 15;94(10):3289-93.
https://www.ncbi.nlm.nih.gov/pubmed/10552937
Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, Gentilini P, Guardigni L, Gobbi M, Fattori PP, Falini B, Lauta VM, Bendandi M, Gherlinzoni F, De Renzo A, Zaja F, Mazza P, Volpe E, Bocchia M, Aitini E, Tabanelli M, Leone G, Tura S. Elderly aggressive-histology non-Hodgkin’s lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood. 1999 Jul 1;94(1):33-8.
https://www.ncbi.nlm.nih.gov/pubmed/10381495
Zinzani PL, Martelli M, Magagnoli M, Zaccaria A, Ronconi F, Cantonetti M, Bocchia M, Marra R, Gobbi M, Falini B, Gherlinzoni F, Moretti L, De Renzo A, Mazza P, Pavone E, Sabattini E, Amendola A, Bendandi M, Pileri SA, Mandelli F, Tura S. Anaplastic large cell lymphoma Hodgkin’s-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood. 1998 Aug 1;92(3):790-4.
https://www.ncbi.nlm.nih.gov/pubmed/9680346
Magagnoli M, Sarina B, Balzarotti M, Castagna L, Timofeeva I, Nozza A, Bertuzzi A, Siracusano L, Sinnone M, Santoro A. Mobilising potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma . Bone Marrow Transplant 2001; 28; 923-27.
https://www.ncbi.nlm.nih.gov/pubmed/11753545
Masci G, Magagnoli M, Zucali Pa, Castagna L, Carnaghi C, Sarina B, Pedicini V, Fallini M, Santoro A. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-fluorouracil-based chemotherapy? J Clin Oncol 2003; 21, 736.
https://www.ncbi.nlm.nih.gov/pubmed/12586814
Magagnoli M, Masci G, Zucali Pa, Castagna L, Carnaghi C, Sarina B, Pedicini V, Fallini M, Santoro A. Minidose warfarin is associated with high incidence of international Normalized Ratio (INR) elevation during chemotherapy with FOLFOX regimen Ann Oncol. 2003 Jun;14(6):959-60.
https://www.ncbi.nlm.nih.gov/pubmed/12796035
Magagnoli M, Castagna L, Bramanti S, Balzarotti M, Santoro A Single-agent high dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen Bone Marrow Transplant ,2004, 33: 1067-68.
https://www.ncbi.nlm.nih.gov/pubmed/15129236
Magagnoli M, Castagna L, Masci G, Santoro A. Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-fluorouracil-based chemotherapy ? Oncology 2004, 9, 594-95.
https://www.ncbi.nlm.nih.gov/pubmed/15477645
Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma Haematologica. 2007 Jan;92(1):35-41.
https://www.ncbi.nlm.nih.gov/pubmed/17229633
Conconi A, Raderer M, Franceschetti S, Devizzi L, Ferreri AJ, Magagnoli M, Arcaini L, Zinzani PL, Martinelli G, Vitolo U, Kiesewetter B, Porro E, Stathis A, Gaidano G, Cavalli F, Zucca E Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. .Br J Haematol. 2014 Jul;166(1):69-76.
https://www.ncbi.nlm.nih.gov/pubmed/24673512
Dr. Stefan Barta, MD, MRCP(UK)
Stefan K. Barta, MD, MRCP(UK) underwent medical training at the Johann Wolfgang Goethe University Frankfort, Germany. He completed his internal medicine training at the St. Bartholomew’s and The Royal London Hospital, UK and his hematology-oncology fellowship at the Montefiore Medical Center/Albert-Einstein College of Medicine, Bronx, New York. Previously, Dr. Barta led the T-cell lymphoma program at the Fox Chase Cancer Center. He is currently an Associate Professor of Medicine at the University of Pennsylvania, and is in charge of the T Cell Lymphoma Program. His research interests are focused on novel therapies in T-cell and other aggressive lymphomas. He was awarded with an American Society of Clinical Oncology (ASCO) Young Investigator Award in 2010. Since then, he has led and/or developed multiple investigational clinical trials for lymphoma either as study chair, principal investigator or site principal investigator. He serves on the lymphoma committees for the Eastern Cooperative Oncology Group (ECOG-ACRIN) and AIDS Malignancy Consortium (AMC) and is a member of the AMC steering committee. He is reviewer for several oncological journals and is on the editorial board for “Clinical Lymphoma, Myeloma & Leukemia”.
Relevant Publications
Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leuk Lymphoma. 2018 [Epub ahead of print].
https://www.ncbi.nlm.nih.gov/pubmed/30277110
Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang CJ, Dwyer MA, Freedman-Cass DA. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(8):986-1017.
https://www.ncbi.nlm.nih.gov/pubmed/30099375
Tan CRC, Abdul-Majeed S, Cael B, Barta SK. Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. Clin Pharmacokinet. 2018 [Epub ahead of print].
https://www.ncbi.nlm.nih.gov/pubmed/29802543
Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. J Natl Compr Canc Netw. 2018;16(2):123-135.
https://www.ncbi.nlm.nih.gov/pubmed/29439173
Wahab A, Kesari K, J Smith S, Liu Y, Barta SK. Type B lactic acidosis, an uncommon paraneoplastic syndrome. Cancer Biol Ther. 2018;19(2):101-104.
https://www.ncbi.nlm.nih.gov/pubmed/29293400
Wang TP, Scott JH, Barta SK.The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.
Ther Adv Hematol. 2017 Dec;8(12):329-344.
https://www.ncbi.nlm.nih.gov/pubmed/29204260
Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017 Jul 10;35(20):2260-2267
https://www.ncbi.nlm.nih.gov/pubmed/28475457
Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).
Cancer. 2016 Oct;122(19):2996-3004
https://www.ncbi.nlm.nih.gov/pubmed/27351685
Ratner L, Rauch D, Abel H, Caruso B, Noy A, Barta SK, Parekh S, Ramos JC, Ambinder R, Phillips A, Harding J, Baydoun HH, Cheng X, Jacobson S. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J. 2016 Mar 25;6:e408.
https://www.ncbi.nlm.nih.gov/pubmed/27015285
Barta SK.To be or not to be HIV+, that is no longer the question. Blood. 2015 Jul 9;126(2):124-6
https://www.ncbi.nlm.nih.gov/pubmed/26160183
Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Little RF, Dunleavy K, Wilson WH, Wyen C, Remick SC, Kaplan LD, Ratner L, Noy A, Sparano JA. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.
Ann Oncol. 2015 May;26(5):958-66
https://www.ncbi.nlm.nih.gov/pubmed/25632071
Bachegowda LS, Barta SK.Genetic and molecular targets in lymphoma: implications for prognosis and treatment. Future Oncol. 2014 Dec;10(15):2509-28
https://www.ncbi.nlm.nih.gov/pubmed/25525858
Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica. 2014 Nov;99(11):1731-7
https://www.ncbi.nlm.nih.gov/pubmed/25150257
Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.Blood. 2013 Nov 7;122(19):3251-62
https://www.ncbi.nlm.nih.gov/pubmed/24014242
Dr. Matthew Matasar, MD
Dr. Matthew Matasar is a board-certified medical oncologist/hematologist, who received his undergraduate and medical degrees from Harvard University. His internal medicine training was completed at Columbia Presbyterian, where he earned a Master’s in biostatistics, while serving as Chief Resident. His fellowship training was in medical oncology at Memorial Sloan Kettering Cancer Center, where he subsequently joined faculty on the Lymphoma and Adult BMT services. Dr. Matasar is also the Director of the Lymphoma Survivorship Clinic, where he focuses on the management of long-term survivors of Hodgkin and non-Hodkgin lymphoma. As a member of the lymphoma and BMT services, his research is aimed to explore the management of aggressive lymphomas, focusing on improving outcomes in relapsed but curable patients using novel therapy and stem cell transplantation techniques. His primary research interest is in developing a research program to better understand the optimal care of lymphoma survivors, focusing on reducing the risk and improving the management of late effects of chemotherapy and radiation therapy. He is the Chief of Medical Oncology at MSK Bergen, directing a team of expert medical oncologists in the delivery of cutting-edge care to patients at our outpatient center in Montvale, New Jersey.
Relevant Publications
Kara Franco , MPH, Elyse Shuk , MA, Errol Philip , PhD, Danielle Blanch-Hartigan , PhD, MPH, Patricia A. Parker , PhD, Matthew Matasar , MD, Steven Horwitz , MD, David Kissane , MD, Smita C. Banerjee , PhD & Carma L. Bylund , PhD Communication between oncologists and lymphoma survivors during follow-up consultations: A qualitative analysis, journal of Psychosocial Oncology, Pages 513-530 | Accepted author version posted online: 30 Mar 2017, Published online: 30 Mar 2017 http://www.tandfonline.com/doi/full/10.1080/07347332.2017.1313352?scroll=top&needAccess=true
Talya Salz, Emily Craig Zabor, Peter de Nully Brown, Susanne Oksbjerg Dalton, Nirupa Jaya Raghunathan, Matthew J. Matasar, Richard Steingart, Henrik Hjalgrim, Peter Svenssen Munksgaard, Lena Specht, Andrew J. Vickers, Kevin C. Oeffinger, Christoffer Johansen The contribution of pre- existing cardiovascular (CV) risk factors to the risk of stroke or heart attack among non-Hodgkin lymphoma (NHL) survivors. Journal of Clinical Oncology, 10082, 2017 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.10082
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH. Blood. 2017 Sep 5. pii: blood-2017-06-788877. doi: 10.1182/blood-2017-06-788877. [Epub ahead of print] PMID:28874350 http://www.bloodjournal.org/content/early/2017/09/05/blood-2017- 06-788877?sso-checked=true
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.PMID: 28314788 http://clincancerres.aacrjournals.org/content/early/2017/05/17/1078-0432.CCR-16-3068
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. Biol Blood Marrow Transplant. 2017 Jan;23(1):38-43. doi: 10.1016/j.bbmt.2016.09.024. Epub 2016 Oct 3. PMID:27713090 http://www.sciencedirect.com/science/article/pii/S1083879116303871
Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS1, Briggs
S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro
Multicenter Phase II Study of Temozolomide and Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Newly Diagnosed Anaplastic Oligodendroglioma. Neuro Oncol. 2017 May 2. doi: 10.1093/neuonc/nox086. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28472509
Communication between Oncologists and lymphoma survivors during follow-up consultations: A qualitative analysis. Franco K, Shuk E, Philip E, Blanch-Hartigan D, Parker PA, Matasar M, Horwitz S, Kissane DW, Banerjee SC, Bylund CL. Journal of Psychosocial Oncology. March 2017 http://www.tandfonline.com/doi/abs/10.1080/07347332.2017.1313352
Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Gunjan L. Shah, Michael Scordo, Sean Devlin, Joachim Yahalom, Matthew J Matasar, Alison Moskowitz, Sergio A. Giralt, Craig H. Moskowitz. Biology of Blood and Bone Marrow Transplant. 2017 Volume 23 Issue 3 (S142- S143) http://www.bbmt.org/article/S1083-8791(16)30808-4/fulltext
Kara Franco, Elyse Shuk, Errol Philip, Danielle Blanch-Hartigan, Patricia A. Parker, Matthew Matasar, Steven Horwitz, David Kissane, Smita C. Banerjee, and Carma L. Bylund, Communication between oncologists and lymphoma survivors during
follow-up consultations: A qualitative analysis JOURNAL OF PSYCHOSOCIAL ONCOLOGY 0 , ISS. JA,0 2017
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. Biol Blood Marrow Transplant. 2017 Jan;23(1):38-43. doi: 10.1016/j.bbmt.2016.09.024.PMID: 27713090 https://www.ncbi.nlm.nih.gov/pubmed/27713090
Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. Andreas Rimner MD, Shina Lovie MPH, Meier Hsu MS, Monica Chelius BS, Zhiganh Zhang PhD, Karen Chau AB, Alison J Moskowitz MD, Matthew Matasar MD, Craig Moskowitz MD, Joachim Yalhalom MD. International Journal of Radiation Oncology. 2017 volume 97 Issue 5 (1066-1076) http://www.redjournal.org/article/S0360-3016(17)30285-7/abstract
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MD, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. J Clin Oncol. 2017 Feb:JCO2016690198. [Epub ahead of print]PMID:28029326 http://ascopubs.org/doi/abs/10.1200/JCO.2016.69.0198
Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post- Rituximab Era. Batlevi, C., Alperovich, A., Smith, K., Ying, Z., Soumerai, J. D., Copeland, A. R., Joffe, E., Caron, P., Drullinsky, P., Gerecitano, J. F., Hamilton, A., Hamlin, P. A., Horwitz, S. M., Intlekofer, A. M., Kumar, A., Matasar, M. J., Moskowitz, A. J., Moskowitz, C. H., Noy, A., Palomba, M. L., Portlock, C. S., Sauter, C. S., Straus, D. J., Zelenetz, A. D., Ni, A., Seshan, V. E., & Younes, A. Blood, 128(22), 4119. http://www.bloodjournal.org/content/128/22/4119
What Is the Cost of Disease Progression Among Patients with Indolent or Aggressive Non-Hodgkin Lymphoma (NHL)? Engel-Nitz, N., Dacosta Byfield, S., Bancroft, T., Amy, J., Reyes, C., Chen, M., & Matasar, M. J. Blood, 128(22), 5957. http://www.bloodjournal.org/content/128/22/5957
Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Vardhana, S. A., Sauter, C. S., Matasar, M. J., Zelenetz, A. D., Galasso, N., Woo, K. M., Zhang, Z. and Moskowitz, C. H.16 Dec 2016 Br J Hematology. doi:10.1111/bjh.14453 http://onlinelibrary.wiley.com/doi/10.1111/bjh.14453/full
Maria Gil-Cupello BA, Gunjan L. Shah MD MS, Molly A. Maloy MS, Debra A. Goldman MS, Sean M. Devlin PhD, Matthew J. Matasar MD MS, Sergio Giralt MD, Craig S. Sauter MD, Craig H. Moskowitz MD, Miguel- Angel Perales MD. Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after
Autologous Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation , Volume 22 ,Issue 3 , S232 – S233 https://www.ncbi.nlm.nih.gov/pubmed/27982423
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Shah GL, Yahalom J, Matasar MJ, Verwys SL, Goldman DA, Bantilan KS, Zhang Z, McCall SJ, Moskowitz AJ, Moskowitz CH.Br J Haematol. 2016 Nov;175(3):440-447. doi: 10.1111/bjh.14245.PMID: 27377168Late Cardiac Effects of Therapy for Hodgkin Lymphoma, Matasar M, Gupta D. Clin Oncol. 2016; 1: 1042. http://www.clinicsinoncology.com/pdfs_folder/cio-v1-id1042.pdf
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation. Maria Gil-Cupello BA, Gunjan L. Shah MD MS, Molly A. Maloy MS, Debra A. Goldman MS, Sean M. Devlin PhD, Matthew J. Matasar MD MS, Sergio Giralt MD, Craig S. Sauter MD, Craig H. Moskowitz MD, Miguel-Angel Perales MD. Biology of Blood and Marrow Transplantation , Volume 22 , Issue 3 , S232 – S233 http://www.bbmt.org/article/S1083- 8791(15)01398-1/abstract
Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. Soumerai, J. D., Bantilan, K. S., Ni, A., Batlevi, C., Alperovich, A., Smith, K., Ying, Z., Copeland, A. R., Matasar, M. J., Straus, D. J., Gerecitano, J. F., Hamlin, P. A., Horwitz, S. M., Portlock, C. S., Palomba, M. L., Moskowitz, C. H., Moskowitz, A. J., Noy, A., Sauter, C. S., Kumar, A., Intlekofer, A. M., Caron, P., Drullinsky, P., Younes, A., & Zelenetz, A. D. Blood, 128(22), 1777 http://www.bloodjournal.org/content/128/22/1777
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH. Blood. 2016 Sep 15;128(11):1458-64. doi: 10.1182/blood- 2016-03-703470. PMID: 27458003 http://www.bloodjournal.org/content/128/11/1458
Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588 30. Sauter, C. S., Verwys, S. L., McCall, S. J., Miller, S. T., Courtien, A. I., Schoder, H., Harris, P., Matasar, M. J., Younes, A., & Moskowitz, C. H. Blood, 128(22), 4198. http://www.bloodjournal.org/content/128/22/4198?sso-checked=true
Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. 32. Alperovich, A., Batlevi, C., Smith, K., Ying, Z., Soumerai, J. D., Copeland, A. R., Joffe, E., Caron, P., Drullinsky, P., Gerecitano, J. F., Hamilton, A., Hamlin, P. A., Horwitz, S. M., Intlekofer, A. M., Kumar, A., Matasar, M. J., Moskowitz, A. J., Moskowitz, C. H., Noy, A., Palomba, M. L., Portlock, C. S., Sauter, C. S., Straus, D. J., Zelenetz, A. D., Ni, A., Seshan, V. E., & Younes, A. Blood, 128(22), 2955. http://www.bloodjournal.org/content/128/22/2955
Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Pharmacokinetically-Targeted (PK) Busulfan (Bu), Cyclophosphamide (TBC) Conditioning, Michael Scordo MD, Valkal Bhatt PharmD, Meier Hsu MS, Antonio M. Omuro MD, Matthew J. Matasar MS MD, Lisa DeAngelis MD, Parastoo Dahi MD, Craig H. Moskowitz MD, Sergi Giralt MD, Craig S. Sauter MD. Biology of Blood and Marrow Transplantation , Volume 22 , Issue 3 , S132 – S133 http://www.bbmt.org/article/S1083-8791(15)01222-7/abstract
Protocol for a cluster randomised trial of a communication skills intervention for physicians to facilitate survivorship transition in patients with lymphoma. Parker PA, Banerjee SC, Matasar MJ, Bylund CL, Franco K, Li Y, Levin TT, Jacobsen PB, Astrow AB, Leventhal H, Horwitz S, Kissane DW. BMJ Open. 2016 Jun 28;6(6):e011581. doi: 10.1136/bmjopen-2016-011581. PMID: 27354079 https://www.ncbi.nlm.nih.gov/pubmed/27354079
Pattern and Prognostic Implications of Cardiac Metastases Among Patients With Advanced Systemic Cancer Assessed With Cardiac Magnetic Resonance Imaging. Pun SC, Plodkowski A, Matasar MJ, Lakhman Y, Halpenny DF, Gupta D, Moskowitz C, Kim J, Steingart R, Weinsaft JW. J Am Heart Assoc. 2016 May 4;5(5). pii: e003368. doi: 10.1161/JAHA.116.003368.PMID: 27146445 https://www.ncbi.nlm.nih.gov/pubmed/27146445
Cancer and Fertility Program Improves Patient Satisfaction With Information Received. Kelvin JF, Thom B, Benedict C, Carter J, Corcoran S, Dickler MN, Goodman KA, Margolies A, Matasar MJ, Noy A, Goldfarb SB. J Clin Oncol. 2016 May 20;34(15):1780-6. doi: 10.1200/JCO.2015.64.5168. PMID: 27044937 http://ascopubs.org/doi/abs/10.1200/JCO.2015.64.5168
Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Schöder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, Moskowitz A, Noy A, Palomba L, Portlock C, Straus D, Grewal R, Migliacci JC, Larson SM, Moskowitz J Nucl Med. 2016 May;57(5):728-34. doi: 10.2967/jnumed.115.166769. PMID: 26719374 http://jaha.ahajournals.org/content/5/5/e003368.short
Survivorship care planning after participation in communication skills training intervention for a consultation about lymphoma survivorship. Banerjee SC, Matasar MJ, Bylund CL, Horwitz S, McLarney K, Levin T, Jacobsen PB, Parker P, Astrow A, Kissane DW. Transl Behav Med. 2015 Dec;5(4):393-400. doi: 10.1007/s13142-015-0326-z. PMID: 26622912 https://www.ncbi.nlm.nih.gov/pubmed/26622912
Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). Dang, T. O., Ni, A., Gerecitano, J. F., Hamlin, P. A., Hohl, T. M., Kumar, A., Moskowitz, A. J., Moskowitz, C. H., Noy, A., Palomba, L., Portlock, C. S., Matasar, M. J., Younes, A., Zelenetz, A. D., & Straus, D. J. ). Blood (2016), 128(22), 1778. http://www.bloodjournal.org/content/128/22/1778
Imaging for Staging and Response Assessment in Lymphoma. Johnson SA, Kumar A, Matasar MJ, Schöder H, Rademaker J. Radiology. 2015 Aug;276(2):323-38. doi: 10.1148/radiol.2015142088. Review. PMID: 26203705 https://www.ncbi.nlm.nih.gov/pubmed/26203705
Tissue characteristics and anatomic distribution of cardiac metastases among patients with advanced systemic cancer assessed by cardiac magnetic resonance (CMR) Shawn Pun 1 , Andrew Plodkowski 3 , Dipti Gupta 1 , Yuliya Lakhman 3 , Darragh F Halpenny 3 , Matthew J Matasar 2 , Angel Chan 1 , Jennifer Liu 1 , Richard Steingart 1 and Jonathan W Weinsaft 1.Journal of the American Heart Association. 2016;5:e003368, originally published May 4, 2016 http://go.galegroup.com/ps/anonymous?p=AONE&sw=w&issn=10976647&v=2.1&it=r&id=GALE%7CA45271 6919&sid=googleScholar&linkaccess=fulltext&authCount=1&isAnonymousEntry=true
Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell, Soumerai, J. D., Zelenetz, A. D., Moskowitz, C. H., Younes, A., Palomba, M. L., Hamlin, P. A., Noy, A., Horwitz, S. M., Matasar, M. J., Moskowitz, A. J., Portlock, C. S., Straus, D. J., Chen, A., Little, R. F., France, F., Whang, J., Mishra, N., Jarjies, C., & Gerecitano, J. F. . Blood, 126(23), 2691 http://www.bloodjournal.org/content/126/23/2691
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, Hilden P, Devlin SM, Zelenetz AD, Moskowitz CH. Blood. 2015 Apr 16;125(16):2579-81. doi: 10.1182/blood-2014-10- 606939. PMID: 25758829 https://www.ncbi.nlm.nih.gov/pubmed/25758829
Distress and Perceived Impact on Well-Being for Low- or Intermediate-Risk and High-Risk Patients with Chronic Lymphocytic Leukemia (CLL) Buzaglo, J. S., Miller, M. F., Karten, C., Weiss, E. S., Tomlinson, , Andersen, B. L., Matasar, M. J., Byrd, J. C., & Flowers, C. (2016). Blood, 128(22), 5970 http://www.bloodjournal.org/content/128/22/5970
A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas 33.Mehta-Shah, N., Moskowitz, A. J., Lunning, M., Lynch, P., Scheuerman, M., Kumar, A., Gerecitano, J. ,
Zelenetz, A. D., Hamlin, P. A., Noy, A., Matasar, M. J., et al. (2016). Blood, 128(22), 2991 http://www.bloodjournal.org/content/128/22/2991?sso-checked=true
Real-World Health Care Utilization and Costs Among Patients Newly Initiating Systemic Therapy for Chronic Lymphocytic Leukemia (CLL) in the United States Matasar, M. J., Dacosta Byfield, S., Blauer-Peterson, C., Montez, M., Reyes, C., & Masaquel, A. (2016). Blood, 128(22), 5928 http://www.bloodjournal.org/content/128/22/5928
Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. Blood (2016) Herrera, A. F., Matasar, M. J., Assouline, S., Kamdar, M., Mehta, A., Fleury, I., Kim, W. S., Kim, T. M., Bosch, F., Radford, J. A., Bu, L., Hong, W., & Sehn, L. H. Blood 128(22), 4194 http://www.bloodjournal.org/content/128/22/4194?sso- checked=true
VINCRISTINE OMISSION, BUT NOT DOSE REDUCTION, IS ASSOCIATED WITH DECREASED SURVIVAL IN ELDERLY DLBCL PATIENTS, S. Afifi; A. Michael; M. Azimi; M. Rodriguez; Z. Zhang;
Woo; C. H. Moskowitz; A. Moskowitz; A. Kumar; M. J. Matasar; C. S. Portlock; A. D. Zelenetz; L. Palomba; A. Noy; J. Gerecitano; S. M. Horwitz; D. J. Straus; A. Younes; P. A. Hamlin. Hematological Oncology. 33():212–213, Jun 2015 http://insights.ovid.com/hematological- oncology/honc/2015/06/001/vincristine-omission-not-dose-reduction-associated/236/01445428
Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. Batlevi, C., Rapaport, F., Intlekofer, A. M., Reiner, A., Moskowitz, C. H., Horwitz, S. M., Zelenetz, A. D., Palomba, L., Moskowitz, A. J., Gerecitano, J. F., Hamlin, P. A., Copeland, A. R., Matasar, M. J., Sauter, C. S., et al. (2015). Blood (2015), 126(23), 2668 http://www.bloodjournal.org/content/126/23/2668?sso-checked=true
Are we ready to predict late effects? A systematic review of clinically useful prediction models. Salz T, Baxi SS, Raghunathan N, Onstad EE, Freedman AN, Moskowitz CS, Dalton SO, Goodman KA, Johansen C, Matasar MJ, de Nully Brown P, Oeffinger KC, Vickers AJ. Eur J Cancer. 2015 Apr;51(6):758-66. doi: 10.1016/j.ejca.2015.02.002. Review. https://www.ncbi.nlm.nih.gov/pubmed/25736818
A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning. Scordo, M., Bhatt, V., Hsu, M., Omuro, A. M., Matasar, M. J., DeAngelis, L., Dahi, P. B., Moskowitz, C. H., Giralt, S. A., & Sauter, C. S Blood, 126(23), 4354. http://www.bloodjournal.org/content/126/23/4354
A PHASE I/II TRIAL OF THE COMBINATION OF ROMIDEPSIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA AND MYELOMA. N. Mehta-Shah; M. A. Lunning; J. Ruan; S. Nair; A. M. Boruchov; A. J. Moskowitz; J. F. Gerecitano; P. A. Hamlin; J. P. Leonard; P. Lynch; J. Matasar; C. Moskowitz; C. Portlock; A. Younes; P. Myskowski; P. Nolan; M. L. Palomba; J. Vredenburgh; C. Querfeld; D. J. Straus; A. Zelenetz; H. Schroder; J. Rademaker; W. Schaffer; S. M. Horwitz. Hematological Oncology. 33():108, Jun 2015 http://insights.ovid.com/hematological-oncology/honc/2015/06/001/phase-ii-trial- combination-romidepsin-lenalidomide/35/01445428
CLINICAL, METABOLIC AND MOLECULAR RESPONSES WITH SEQUENTIAL R-CHOP, HIGH-DOSE CYTARABINE, AND IODINE-131 TOSITUMOMAB-BASED TRANSPLANT IN MANTLE CELL LYMPHOMA A. D. Zelenetz; S. F. Schoninger; C. Sauter; G. Ulaner; C. Casulo; M. Faham; K. Kong; A. Dogan; R. Grewal; J. Gerecitano; J. Goldberg; A. Hamilton; P. Hamlin; M. Matasar; C. Moskowitz; A. Noy; Palomba; C. S. Portlock; A. Younes; T. Willis; A. Kumar. Hematological Oncology. 33():206, Jun 2015 http://insights.ovid.com/hematological-oncology/honc/2015/06/001/clinical-metabolic-molecular-responses- sequential/223/01445428
Toxicity of Maintenance Rituximab in Older Adults with Non-Hodgkin Lymphoma. Matasar, M. J., Atoria, C. L., Elkin, E. B., & Nabhan, C. (2015). Blood, 126(23), 881. http://www.bloodjournal.org/content/126/23/881
Late morbidity and mortality in patients with Hodgkin’s lymphoma treated during adulthood. Matasar MJ, Ford JS, Riedel ER, Salz T, Oeffinger KC, Straus DJ. J Natl Cancer Inst. 2015 Feb 24; -2008 107(4). pii: djv018. doi: 10.1093/jnci/djv018. PMID: 25717170 https://www.ncbi.nlm.nih.gov/pubmed/25717170
Dr. Alexey. V Danilov, MD, PhD
Alexey V. Danilov, MD, PhD, is Associate Professor of Medicine at the Knight Cancer Institute Hematology and Medical Oncology, in Portland, Oregon. He earned his medical degree and PhD at Yaroslavl State Medical Academy in Russia and completed a fellowship in hematology/oncology at Tufts Medical Center, in Boston, Massachusetts.
Dr. Danilov runs an independently funded clinical/translational program in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) that bridges the understanding of B-cell biology with early clinical evaluation of novel therapeutics. He spearheads a translational and early-phase therapeutics effort in B-cell malignancies at the Knight Cancer Institute. In the laboratory, he focuses on targeting stromal-mediated pro-survival signaling in lymphoid malignancies. He has characterized promising therapeutic agents with regard to their mechanism of action and resistance, ushering them into early-phase clinical trials in CLL and NHL. He seeks to translate his findings to clinical care by developing protocols that advance current treatment paradigms. His work has received support from the Leukemia & Lymphoma Society, Lymphoma Research Foundation, the National Cancer Institute, and the Southwest Oncology Group, among other funding organizations. He has been published in numerous peer-reviewed journals including Clinical Cancer Research, Cancer Research, Haematologica, Molecular Cancer Therapeutics, Journal of Immunology and others.
Among numerous speaking engagements, Dr. Danilov has chaired sessions at the American Society of Hematology Annual Meetings, and has given visiting professor lectures in London and New York. He is a member of the American Society of Hematology and the European Hematology Association. Dr. Danilov is a Leukemia & Lymphoma Society Scholar in Clinical Research and a Lymphoma Research Foundation Clinical Investigator.
Relevant Publications
Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, Loriaux MM, Spurgeon SE, Danilova OV and Danilov AV. 2017. SYK inhibition thwarts the BAFF – B-cell receptor crosstalk and thereby antagonizes Mcl-1 in CLL. Haematologica. 102 (11): 1890-1900.
https://www.ncbi.nlm.nih.gov/pubmed/28838991
Danilov AV, Lewis LD, Lansigan F, Jones SY, Roudaia L, Highhouse B, Beaulieu BB and Brown JR. 2017. A Phase I dose-ranging study of Bendamustine and Rituximab (BR) in chronic lymphocytic leukemia (CLL) patients with comorbidities. British Journal of Haematology. 178 (5): 820-823.
https://www.ncbi.nlm.nih.gov/pubmed/27377970
Danilov AV, Hu S, Orr B, Godek K, Mustachio LM, Sekula D, Compton D and Dmitrovsky E. 2016. Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cdk1/2. Molecular Cancer Therapeutics. 15(11): 2758-2766.
https://www.ncbi.nlm.nih.gov/pubmed/27550941
Paiva C, Godbersen JC, Soderquist R, Rowland T, Sumner K, Spurgeon SE, Brown JR, Srinivasa SP and Danilov AV. 2015. Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-cells. PLoS One. 10(11): e0143685.
https://www.ncbi.nlm.nih.gov/pubmed/26606677
Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A and Danilov AV. 2014. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-B activation and induces apoptosis in chronic lymphocytic leukemia B-cells. Clinical Cancer Research. 20 (6): 1576-1589.
https://www.ncbi.nlm.nih.gov/pubmed/24634471
Prof. Georg Lenz, MD
Professor Georg Lenz is Director of the Department of Hematology, Oncology and Pneumology at the University Hospital in Muenster, Germany. He started his career as a medical doctor in Munich in 2002 and completed his post-doctoral fellowship at the National Cancer Institute in Bethesda, USA. In 2009, he moved to Berlin and continued his scientific career as Professor of “Molecular pathogenesis of malignant lymphomas” at the Charité – Universitätsmedizin Berlin where he also worked as a Senior Physician at the Medical Clinic of Hematology, Oncology and Tumor Immunology until 2014.
His research focuses on the molecular characterization of malignant lymphomas. Clinically he focuses on trials investigating the efficacy of novel compounds in the therapy of patients with hematological malignancies.
He has published numerous articles in peer-reviewed journals such as the New England Journal of Medicine, Science, Nature, Blood, and the Journal of Clinical Oncology, and he has authored several books and book chapters.
Relevant Publications
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G. Blood. 2017 Jul 20;130(3):310-322.
https://www.ncbi.nlm.nih.gov/pubmed/28202458
B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.
Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G.Blood. 2017 Jan 19;129(3):333-346.
https://www.ncbi.nlm.nih.gov/pubmed/27864294
Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.
Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NC, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G. Blood. 2015 Jan 1;125(1):124-32.
https://www.ncbi.nlm.nih.gov/pubmed/25359993
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G*, Stegmeier F*.Nat Med. 2014 Jan;20(1):87-92.* Equal contributing last and corresponding author.
https://www.ncbi.nlm.nih.gov/pubmed/24362935
5Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, Tawana K, Popov N, O’Riain C, O’Shea D, Carlotti E, Davies A, Lawrie CH, Matolcsy A, Calaminici M, Norton A, Byers RJ, Mein C, Stupka E, Lister TA, Lenz G, Montoto S, Gribben JG, Fan Y, Grosschedl R, Chelala C, Fitzgibbon J. Nat Genet. 2014 Feb;46(2):176-181.
https://www.ncbi.nlm.nih.gov/pubmed/24362818
IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL. Nogai H, Wenzel SS, Hailfinger S, Grau M, Kaergel E, Seitz V, Wollert-Wulf B, Pfeifer M, Wolf A, Frick M, Dietze K, Madle H, Tzankov A, Hummel M, Dörken B, Scheidereit C, Janz M, Lenz P, Thome M, Lenz G. Blood. 2013 Sep 26;122(13):2242-50.
https://www.ncbi.nlm.nih.gov/pubmed/23869088
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A, Wollert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, Dörken B, Janz M, Dirnhofer S, Lenz P, Hummel M, Tzankov A, Lenz G. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12420-5.
https://www.ncbi.nlm.nih.gov/pubmed/23840064
The protease activity of the paracaspase MALT1 is controlled by monoubiquitination. Pelzer C, Cabalzar K, Wolf A, Gonzalez M, Lenz G, Thome M. Nat Immunol. 2013 Apr;14(4):337-45.
https://www.ncbi.nlm.nih.gov/pubmed/23416615
Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.Nagel D, Spranger S, Vincendeau M, Grau M, Raffegerst S, Kloo B, Hlahla D, Neuenschwander M, Peter von Kries J, Hadian K, Dörken B, Lenz P, Lenz G, Schendel DJ, Krappmann D.Cancer Cell. 2012 Dec 11;22(6):825-37.
https://www.ncbi.nlm.nih.gov/pubmed/23238017
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Davis RE*, Ngo VN*, Lenz G*, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Nature. 2010 Jan 7;463(7277):88-92.* Equal first author.
https://www.ncbi.nlm.nih.gov/pubmed/20054396
Stromal gene signatures in large-B-cell lymphomas. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. N Engl J Med. 2008 Nov 27;359(22):2313-23.
https://www.ncbi.nlm.nih.gov/pubmed/19038878
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Science. 2008 Mar 21;319(5870):1676-9.
https://www.ncbi.nlm.nih.gov/pubmed/18323416
Dr. Tycel Phillips, MD
Dr. Tycel Phillips, is a lymphoma specialist with a research and clinical focus on non-hodgkin lymphoma. Dr. Phillips completed his hematology-oncology fellowship at University Hospitals/Case Western University. While at Case Western, Dr. Phillips began to focus on the development of clinical trials utilizing novel agents in lymphoma. He has continued his focus on clinical research upon his appointment at the University of Michigan and in addition has been the site primary investigator on numerous clinical trials in multiple subtypes of lymphoma. Dr. Phillips’s research interests include evaluation of resistance mechanisms in mantle cell lymphoma (MCL), non-cytotoxic chemotherapeutic treatment in frontline MCL, and other novel combinations in relapsed/refractory lymphoma. Dr. Phillips is involved in professional societies including the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH).
Relevant Publications
Phillips TJ, Barr PM, Park SI, Kolibaba K, Caimi PF, Chhabra S, Kingsley EC, Boyd T, Chen R, Carret AS, Gartner EM, Li H, Yu C, Smith DC: A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Pre-published online Aug 22, 2018. Invest New Drugs. doi: 10.1007/s10637-018-0655-0.
https://www.ncbi.nlm.nih.gov/pubmed/30132271
Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P,
Chen X, Barr PM: Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Pre-published online Apr 25, 2018. doi: https://doi.org/10.1182/blo Blood. (In Press).
https://www.ncbi.nlm.nih.gov/pubmed/29695516
Paun O, Phillips T, Fu P, Novoa RA, Honda KS, Lu KQ, Lazarus HM: Cutaneous complications in
hematopoietic cell transplant recipients: impact of biopsy on patient management. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 19(8): 1204-9, 08/2013. PM23688396
https://www.ncbi.nlm.nih.gov/pubmed/23688396
Phillips T, Devata S, Wilcox RA: Challenges and opportunities for checkpoint blockade in T-cell
lymphoproliferative disorders. J Immunother Cancer 4: 95, 01/2016. PM28031823/PMC5170899
https://www.ncbi.nlm.nih.gov/pubmed/28031823
Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D,
Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S,
Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA: Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 127(12): 1559-1563, 03/2016. PM26764355
https://www.ncbi.nlm.nih.gov/pubmed/26764355
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF,
Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M,
Wilkins J, Leonard JP, Kahl BS, Friedberg JW: RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Epub 2016 Dec 19. Br J Haematol 176(5): 759-769, 12/2016. PM27992063
https://www.ncbi.nlm.nih.gov/pubmed/27992063
Murga-Zamalloa C, Polk A, Hanel W, Chowdhury P, Brown N, Hristov AC, Bailey NG, Wang T, Phillips T, Devata S, Poonnen P, Gomez-Gelvez J, Inamdar KV, Wilcox RA: Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. Oncotarget 8 (70): 114474-114480, 01/2017. PM29383095/PMC5777707
https://www.ncbi.nlm.nih.gov/pubmed/29383095
Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett
E, Bravo MC, Martin P: Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol 10(1): 171, 11/2017. PM29096668
https://www.ncbi.nlm.nih.gov/pubmed/29096668
Boonstra PS, Polk A, Brown N, Hristov AC, Bailey NG, Kaminski MS, Phillips T, Devata S, Mayer T,
Wilcox RA. Epub 2017 Sep 25.: A Single Center Phase II Study of Ixazomib in Patients with Relapsed or Refractory Cutaneous or Peripheral T-cell Lymphomas. Am J Hematol 92(12): 1287-1294, 12/2017.
PM28842936
https://www.ncbi.nlm.nih.gov/pubmed/28842936
Ettleson M, Bongers KS, Vitale K, Perissinotti AJ, Phillips T, Marini BL: Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent
hemodialysis: A case report. J Oncol Pharm Pract: 1, 01/2018. (In Press) PM29385883
https://www.ncbi.nlm.nih.gov/pubmed/29385883
Zhang JY, Briski R, Devata S, Kaminski MS, Phillips TJ, Mayer TL, Bailey NG, Wilcox RA: Survival
Following Salvage Therapy for Primary Refractory Peripheral T-Cell Lymphomas (PTCL). Epub 2017 Dec 18 Am J Hematol 93(3): 394-400, 03/2018. (In Press) PM29194714
https://www.ncbi.nlm.nih.gov/pubmed/29194714
Dr. Loretta J. Nastoupil, MD
Loretta Nastoupil, MD, completed her undergraduate degree at Texas Tech Health Sciences Center, graduating summa cum laude in 2003. She obtained her medical degree from the University of Texas Southwestern Medical School at Dallas in 2007. Dr. Nastoupil completed her internship and internal medicine residency at Washington University, Barnes-Jewish Hospital in St. Louis, Missouri. Following residency, she completed a hematology-medical oncology fellowship at Emory University, serving as chief fellow her last year.
Dr. Nastoupil joined the faculty at MD Anderson Cancer Center in 2013 as an assistant professor in the Department of Lymphoma/Myeloma. Dr. Nastoupil is a clinical researcher with a focus on lymphoma epidemiology and outcomes. The goal of her research is to identify risk factors associated with lymphoma and eliminate disparities in outcomes to improve survival for all patients with lymphoma. She is actively involved in early phase drug development as well as immune therapy studies in indolent lymphoma. She is also actively exploring predictive biomarkers with modern therapy in lymphoma.
Relevant Publications
Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 2014;120(12):1830-7.
https://www.ncbi.nlm.nih.gov/pubmed/24668580
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma. 2015;56(5):1295-302.
https://www.ncbi.nlm.nih.gov/pubmed/25263322
Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15(12):1311-8.
https://www.ncbi.nlm.nih.gov/pubmed/25439689
Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Rev Anticancer Ther. 2015;15(5):531-44.
https://www.ncbi.nlm.nih.gov/pubmed/25864967
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol. 2016;172(5):724-34.
https://www.ncbi.nlm.nih.gov/pubmed/26729445
Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017;177(2):263-70.
https://www.ncbi.nlm.nih.gov/pubmed/28340281
Casulo C, Nastoupil L, Fowler NH, Friedberg JW, Flowers CR. Unmet needs in the first-line treatment of follicular lymphoma. Ann Oncol. 2017;28(9):2094-106.
https://www.ncbi.nlm.nih.gov/pubmed/28430865
Dr. Brian Hill, MD, PhD
Dr. Hill is the Director of the Lymphoid Malignancies Program and a Staff Physician in the Cleveland Clinic Taussig Cancer Institute. He received his undergraduate degree from Dartmouth College and earned his Ph.D. in genetics through work done at Cold Spring Harbor Laboratory. He received his medical degree from the University of Chicago Pritzker School of Medicine where he also completed his residency in Internal Medicine. He completed his hematology/oncology fellowship at the Cleveland Clinic. His clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma. He is the principal investigator of multiple on-going clinical trials of new cancer treatments including novel cellular therapies.
Relevant Publications
Winter AM, Landsburg DJ, Mato AR, Isaac K, Hernandez-Ilizaliturri FJ, Reddy N, Smith S, Shadman M, Smith MR, Caimi P, Jagadeesh D, Hill BT. A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. Blood. 2017 [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28794071
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi Y, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol, A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, and Go WY. Axicabtagene Ciloleucel (CD19 CAR T) in Refractory Large B-Cell Lymphoma. NEJM 2017;377(26):2531-2544.
https://www.ncbi.nlm.nih.gov/pubmed/29226797
Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017;10;35(20):2260-2267.
https://www.ncbi.nlm.nih.gov/pubmed/28475457
Hill BT, Ahn KW, Hu ZH, Aljurf M, Beitinjaneh A, Cahn JY, Cerny J, Kharfan-Dabaja MA, Ganguly S, Ghosh N, Grunwald MR, Inamoto Y, Kindwall-Keller T, Nishihori T, Olsson RF, Saad A, Seftel M, Seo S, Szer J, Tallman M, Ustun C, Wiernik PH, Maziarz RT, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biol Blood Marrow Transplant. 2018(3):581-586.
https://www.ncbi.nlm.nih.gov/pubmed/29032274
Prof. Stefano Luminari, MD
Prof Stefano Luminari is Hematologist, Associate professor of Medical Oncology at the University of Modena and Reggio Emilia, in Italy. He is head of the clinical research program for oncohematologic disorders at the Reggio Emilia research Hospital. His activity has been mainly focused on several aspects of clinical research in malignant lymphomas. In particular he is an expert in biomarkers and prognostic studies, in phase II and III clinical trials, and in population based studies. He is an active member of the Fondazione Italiana Linfomi with a leading role in the Indolent lymphoma committee and with a role as PI or co-investigator in several clinical trials mainly focused on follicular lymphomas, Hodgkin lymphomas, aggressive lymphomas (mainly elderly patients) and in the use of PET in lymphomas. He has authored more than 130 peer reviewed manuscripts. Of note, his contribution in the study of FDG-PET in Follicular Lymphoma in the staging (Luminari et al Ann Oncol 2013) and restaging assessment after induction therapy (Luminari et al. Ann Oncol 2014, Trotman J et al. Lancet Hematol 2014) and in the integration of PET with minimal residual disease in the phase of response assessment (Luminari Haematologia 2015). He is active in communicating research data and opinions through social networks (twitter account @stefanoluminari).
Relevant Publications
Luminari S, Ferrari A, Manni et al. . Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. J Clin Oncol. 2017 Nov 2:JCO2017741652. doi: 10.1200/JCO.2017.74.1652.
https://www.ncbi.nlm.nih.gov/pubmed/29095677
Fischer T, Zing NPC, Chiattone CS, Federico M, Luminari S. Transformed follicular lymphoma. Ann Hematol. 2018 Jan;97(1):17-29. doi: 10.1007/s00277-017-3151-2.
https://www.ncbi.nlm.nih.gov/pubmed/29043381
Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, Fortpied C, Gianni AM, Henry-Amar M, Hoskin P, Johnson P, Luminari S, et al. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica. 2017 Oct;102(10):1748-1757. doi: 10.3324/haematol.2017.167478.
https://www.ncbi.nlm.nih.gov/pubmed/28912173
Luminari S, Viel E, Ferreri AJM, etv al. Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. Hematol Oncol. 2017 May 19. doi: 10.1002/hon.2425.
https://www.ncbi.nlm.nih.gov/pubmed/28524259
Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, Grassi I, Casasnovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. J Clin Oncol. 2016 Aug 22.
https://www.ncbi.nlm.nih.gov/pubmed/27551111
Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, et al. . PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood. 2016 Mar 24;127(12):1531-8. doi: 10.1182/blood-2015-11-679407
https://www.ncbi.nlm.nih.gov/pubmed/26747247
Merli F, Luminari S, Gobbi PG, et al. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. J Clin Oncol. 2016 Apr 10;34(11):1175-81. doi: 10.1200/JCO.2015.62.4817.
https://www.ncbi.nlm.nih.gov/pubmed/26712220
Luminari S, Galimberti S, Versari A, Biasoli I, Anastasia A, Rusconi C, Ferrari A, Petrini M, Manni M, Federico M. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica. 2016 Feb;101(2):e66-8. doi: 10.3324/haematol.2015.132811.
https://www.ncbi.nlm.nih.gov/pubmed/26471485
Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Salvi F, Merli F, Anastasia A, Luminari S, et al.. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. J Clin Oncol. 2016 Sep 20;34(27):3293-9. doi: 10.1200/JCO.2016.66.4466.
https://www.ncbi.nlm.nih.gov/pubmed/27382096
Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, et al.. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29. doi: 10.1056/NEJMoa1510093.
https://www.ncbi.nlm.nih.gov/pubmed/27332902
Luminari S, Goldaniga M, Cesaretti M, et al. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2016;57(4):880-7. doi: 0.3109/10428194.2015.1091934.
https://www.ncbi.nlm.nih.gov/pubmed/26379040
Galimberti S, Luminari S, Ciabatti E, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res. 2014 Oct 14. pii: clincanres.0407.2014.
https://www.ncbi.nlm.nih.gov/pubmed/25316810
Trotman J, Luminari S, Boussetta S, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. The Lancet Haematology 1 October 2014 (Volume 1 Issue 1 Pages e17-e27 DOI: 10.1016/S2352-3026(14)70008-0)
https://www.ncbi.nlm.nih.gov/pubmed/27030064
Meignan M, Sasanelli M, Casasnovas RO, Luminari S, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1113-22. doi: 10.1007/s00259-014-2705-y.
https://www.ncbi.nlm.nih.gov/pubmed/24570094
Luminari S, Biasoli I, Versari A, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014 Feb;25(2):442-7. doi: 10.1093/annonc/mdt562.
https://www.ncbi.nlm.nih.gov/pubmed/24412823
Luminari S, Biasoli I, Arcaini L, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013 Aug;24(8):2108-12. doi: 10.1093/annonc/mdt137.
https://www.ncbi.nlm.nih.gov/pubmed/23585513
Federico M, Luminari S, Dondi A, et al.. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Apr 20;31(12):1506-13. doi: 10.1200/JCO.2012.45.0866.
https://www.ncbi.nlm.nih.gov/pubmed/23530110
Luminari S. Bridging the gap between epidemiology and clinical research in lymphoma. Leuk Lymphoma. 2013 Sep;54(9):1855-6. doi: 10.3109/10428194.2013.777838.
https://www.ncbi.nlm.nih.gov/pubmed/23432686